Open Access

Establishment of a patient‑derived mucoepidermoid carcinoma cell line with the CRTC1‑MAML2 fusion gene

  • Authors:
    • Kazuma Noguchi
    • Shuji Kanda
    • Kazunari Yoshida
    • Yusuke Funaoka
    • Koji Yamanegi
    • Kyohei Yoshikawa
    • Kazuki Takaoka
    • Hiromitsu Kishimoto
    • Yoshiro Nakano
  • View Affiliations

  • Published online on: February 2, 2022     https://doi.org/10.3892/mco.2022.2508
  • Article Number: 75
  • Copyright: © Noguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the major and minor salivary glands. Surgical resection is the only curative treatment and there is no effective post‑operative therapy for MEC. The present study reports an Institutional Review Board‑approved case of a 45‑year‑old Japanese female diagnosed with low-grade MEC in the hard palate. Radical resection, supraomohyoid neck dissection and antero‑lateral thigh flap reconstruction was performed. A MEC cell line was then established from the resected tumor tissue. Short tandem repeat profiling confirmed the origin and authenticity of the cell line, that harbors a CRTC1‑MAML2 translocation, which is frequently observed in MEC. Amphiregulin (AREG), identified as one of the targets of the CRTC1‑MAML2 fusion gene, was expressed in the cell line. The AREG receptor, epidermal growth factor receptor (EGFR) was also highly phosphorylated. The results predicted that AREG‑EGFR signaling, which is required for tumor growth and survival, might be activated in the cell line in a cell‑autonomous manner. As AREG expression is associated with EGFR‑targeted drug resistance, this cell line might assist with the identification of novel strategies for MEC treatment.
View Figures
View References

Related Articles

Journal Cover

March-2022
Volume 16 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Noguchi K, Kanda S, Yoshida K, Funaoka Y, Yamanegi K, Yoshikawa K, Takaoka K, Kishimoto H and Nakano Y: Establishment of a patient‑derived mucoepidermoid carcinoma cell line with the <em>CRTC1‑MAML2</em> fusion gene. Mol Clin Oncol 16: 75, 2022
APA
Noguchi, K., Kanda, S., Yoshida, K., Funaoka, Y., Yamanegi, K., Yoshikawa, K. ... Nakano, Y. (2022). Establishment of a patient‑derived mucoepidermoid carcinoma cell line with the <em>CRTC1‑MAML2</em> fusion gene. Molecular and Clinical Oncology, 16, 75. https://doi.org/10.3892/mco.2022.2508
MLA
Noguchi, K., Kanda, S., Yoshida, K., Funaoka, Y., Yamanegi, K., Yoshikawa, K., Takaoka, K., Kishimoto, H., Nakano, Y."Establishment of a patient‑derived mucoepidermoid carcinoma cell line with the <em>CRTC1‑MAML2</em> fusion gene". Molecular and Clinical Oncology 16.3 (2022): 75.
Chicago
Noguchi, K., Kanda, S., Yoshida, K., Funaoka, Y., Yamanegi, K., Yoshikawa, K., Takaoka, K., Kishimoto, H., Nakano, Y."Establishment of a patient‑derived mucoepidermoid carcinoma cell line with the <em>CRTC1‑MAML2</em> fusion gene". Molecular and Clinical Oncology 16, no. 3 (2022): 75. https://doi.org/10.3892/mco.2022.2508